OctoPlus lands formulation work

Netherlands-based drug-delivery specialist OctoPlus will perform formulation development and clinical manufacturing for an unnamed mid-sized European drug maker. The work encompasses three products, now in Phase I to Phase III clinical development.

The contract "significantly contributes" to its annual revenues, the company says.

In June, OctoPlus opened and began production in a manufacturing facility in Leiden, the culmination of a 2-1/2-year effort. The facility, which is being used to produce final drug product, is approved by Dutch authorities to manufacture drugs to international GMP guidelines. The plant more than doubles OctoPlus manufacturing capacity. It also allows the company to make products covering all phases of preclinical drug development, as well as small-scale commercial supplies of injectable pharmaceutical products and other complex formulations.

- here's the contract announcement
- see the new facility release

Suggested Articles

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.

A Chinese OTC drugmaker gets the distinction of ringing in the new year as the first company to be slapped with an FDA warning letter.